This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amphastar Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01174732
First received: July 29, 2010
Last updated: April 17, 2017
Last verified: April 2017
  Purpose
This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover and dose-ranging design. This study aims to evaluate the efficacy and initial safety profiles, and to identify the optimum dose of A006, from a select dose-range for future clinical PK/PD and Phase III studies. This study is to be conducted in generally healthy, adult subjects who have mild-to-moderate persistent asthma for at least 6 months prior to Screening.

Condition Intervention Phase
Asthma Bronchospasm Drug: albuterol inhalation powder Drug: Placebo Drug: albuterol inhalation aerosol Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Phase II Study Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Cross-over and Dose-ranging Study of A006 DPI, Albuterol Inhalation Powder, in Adult Asthma Patients

Resource links provided by NLM:


Further study details as provided by Amphastar Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • AUC [ Time Frame: 5, 20, 40, 60, 90; 120, 180, 240, and 360 minutes post-dose. ]
    Area under the curve (AUC) of post-dose FEV1 percentage changes from the Pre-dose Baseline. The primary analysis of the primary endpoint is to compare the AUC0-t of FEV1, between the A006 treatments and the Placebo Control.


Secondary Outcome Measures:
  • Time to Effect [ Time Frame: 0 to 360 minutes ]
    Time to onset of bronchodilator effect

  • Peak Response [ Time Frame: 0 - 360 minutes ]
    peak bronchodilator response

  • Duration [ Time Frame: 0 - 360 minutes ]
    Duration of effect

  • Response Rate [ Time Frame: 0 - 360 minutes ]
    Bronchodilatory Response Rate

  • Hand Tremor [ Time Frame: within 5 min. prior to dosing and 50 and 360 min post-dose. ]
    Evaluation of hand tremor

  • Vital Signs [ Time Frame: within 15 min. prior to dosing, and 30, 90 and 360 min post-dose. ]
    Pulse, heartrate, respirations, blood pressure

  • 12 lead ECG [ Time Frame: within 15 min. prior to dosing and at 50 and 360 min postdose. ]
    12-lead ECG for routine and QT/QTc evaluations

  • Blood Work [ Time Frame: within 15 min. prior to dosing, and 30 and 120 min. postdose ]
    Collect blood samples (~5 mL) for serum glucose and K+ tests


Enrollment: 26
Study Start Date: July 2010
Study Completion Date: January 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: T1
A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation
Drug: albuterol inhalation powder
A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
Experimental: T2
A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation
Drug: albuterol inhalation powder
A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
Experimental: T3
A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
Drug: albuterol inhalation powder
A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
Experimental: T4
A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations
Drug: albuterol inhalation powder
A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
Placebo Comparator: P
Placebo, 2 inhalations
Drug: Placebo
placebo, lactose inhalation carrier
Active Comparator: R1
Proventil 90 mcg/inhalation, 2 inhalations
Drug: albuterol inhalation aerosol
albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
Other Name: Proventil
Active Comparator: R2
Proventil 90 mcg/inhalation, 4 inhalations
Drug: albuterol inhalation aerosol
albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
Other Name: Proventil

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • With mild-to-moderate persistent asthma for at least 6 months and having used inhaled beta-agonist for asthma control;
  • Must demonstrate response to beta 2 agonist by Reversing;
  • Must demonstrate ability to use DPI;
  • Females of child-bearing potential must be non-pregnant, non-lactating, and practicing a clinically acceptable form of birth control;
  • Additional Criteria

Exclusion Criteria:

  • Smoking history of ≥ 10 pack-years, or having smoked within 6 months;
  • Upper respiratory tract infections
  • Asthma exacerbations;
  • Known intolerance or hypersensitivity to any of the ingredients of the study drug or Proventil®;
  • Use of prohibited drugs or failure to observe the drug washout restrictions;
  • Having been on other clinical drug/device studies in the last 30 days;
  • Other Criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01174732

Locations
United States, California
Amphastar Site 0001
San Jose, California, United States, 95117
United States, Colorado
Amphastar Site 0007
Centennial, Colorado, United States, 80112
Amphastar Site 0008
Denver, Colorado, United States, 80230
Amphastar Site 0039
Lakewood, Colorado, United States, 80401
Sponsors and Collaborators
Amphastar Pharmaceuticals, Inc.
Investigators
Study Director: Safety Monitor Amphastar Pharmaceuticals, Inc.
  More Information

Responsible Party: Amphastar Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01174732     History of Changes
Other Study ID Numbers: API-A006-CL-B
Study First Received: July 29, 2010
Last Updated: April 17, 2017

Keywords provided by Amphastar Pharmaceuticals, Inc.:
asthma
bronchospasm
COPD
chronic respiratory disease

Additional relevant MeSH terms:
Asthma
Bronchial Spasm
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 28, 2017